Rigetti's 7% Jump Gets a Test: Is Wedbush Right That Q2 Shows Real Progress?

Q2 improved the story, but the real test is repeatable commercial demand

This is less about whether Rigetti matters in principle than about whether the company is moving from scientific progress toward repeatable sales.

What the quarter actually showed

The immediate catalyst was straightforward: Rigetti reported Q2 results, and the stock's more than 7% jump showed investors were looking for proof. The headline figure was $5.1 million in second-quarter revenue. In dollar terms that is still small, but it matters because it strengthens the idea that Rigetti is becoming more than a demo-stage story. Before the release, investors were already focused on whether Q2 results scheduled to report on Aug. 6 would show recognition of remaining Novera QPU order revenue.

For a company this early in commercialization, revenue durability matters more than near-term profitability. Rigetti posted an operating loss of $28.1 million, so the better near-term question is not whether it is profitable today, but whether customer engagement is becoming more consistent. The company also ended the quarter with $541.3 million in cash, cash equivalents, and available-for-sale investments, giving it time to keep building. The risk is simple: if sales stay intermittent, investors may stop treating this as a commercial ramp and start treating it as a costly research bet.

Why Wedbush sees progress - and why Q2 alone does not settle the debate

The operating arc is improving, but the business is still early

Wedbush is not arguing that Rigetti has a mature profit engine. It is arguing that the operating trend looks cleaner: Rigetti's revenue rose to $5.1 million from $1.8 million, while gross margin improved to approximately 43% from 31%. That suggests the company's economics around system sales improved quarter over quarter, even if the scale is still small.

The commercial picture also looks more visible than in earlier phases. Rigetti had already noted that the 108-qubit Cepheus-1 system was broadly available during the first quarter, and Wedbush pointed to a broader commercial reach that includes Moody's and Standard Chartered relationships alongside other ecosystem ties. That does not prove a full ramp, but it does make the setup look less like one-off project revenue.

Why the next real rerating catalyst could be Q4

The more important near-term test may be whether the $8.4 million C-DAC 108-qubit system order is recognized in Q4, as MarketBeat's earnings report framed it. If that happens, it would suggest Rigetti is building toward a more meaningful revenue base rather than leaning on a small but improving quarter.

There is also the question of public-sector support. Wedbush cited a proposed agreement for up to $100 million in funding over three years from the U.S. Department of Commerce, and MarketBeat offered a useful caveat: the funding is not yet definitive and would involve equity issuance. So the signal is real, but it is not free of execution or dilution risk.

Where the bear case still holds

Skeptics still have a valid point. MarketBeat's coverage of the earnings call noted that customers are still primarily conducting research rather than commercially valuable quantum-advantage workloads. That keeps the core line in place: research demand can support momentum, but it is not the same as proven commercial-scale adoption.

What can actually reprice Rigetti from here

The market will focus on conversion, not headlines

Wedbush is already looking past this quarter to Q4 2026 revenue of $14.8 million and full-year revenue of $30.5 million. Those figures are substantially above the recent run rate, so the next debate will be less about narrative and more about conversion: whether interest, access, and deployments are turning into recognizable revenue and repeatable demand.

Fidelity has to matter to customers, too

Technology progress only matters if it changes why and how customers use the system. Rigetti reported median two-qubit fidelity of roughly 99.1% and was targeting 99.5% later this year. If that target holds, bulls have a clearer bridge from research usage to stronger commercial value. If it slips, skeptics will argue customers still lack a decisive reason to move beyond experimentation.

What would weaken the setup

The story weakens if: - revenue remains lumpy and dependent on occasional wins - customer usage stays mostly experimental rather than commercial - fidelity improvements slow or slip - funding signals remain non-definitive or introduce meaningful dilution

That is the live checklist now: conversion, adoption, fidelity, and funding. If those signals keep improving, Wedbush's "progress" call becomes easier to defend. If they do not, Rigetti remains an interesting science story with better packaging, not yet a proven commercial ramp.